Matthew Jones

Partner, Solicitor

Matthew Jones

Matthew has extensive experience of acting in large scale UK patent litigation and in multi-jurisdictional patent litigation. Matthew has acted in litigation relating to a wide range of technologies, including electronics, telecommunications, cryptography, optics, mechanical devices, pharmaceuticals and biotechnology.

Before joining EIP, Matthew worked as Senior Counsel for Teva Pharmaceuticals Europe. During his time at Teva, Matthew managed high-profile litigation in the UK, Germany, France and the Netherlands, including Generics [UK] Ltd v Yeda & Teva, which related to the blockbuster drug Copaxone®. Prior to working at Teva, Matthew worked as a solicitor at McDermott Will & Emery and at Taylor Wessing. Matthew is well placed to advise clients on the new Unified Patent Court (UPC) - see further details at EIP Amar, our alliance created to support clients in any litigation before the UPC.

Matthew has a degree in Biochemistry from Bristol University and a PhD in Biochemistry (specialising in quantum enzymology) from Leicester University. He has written papers published in peer-reviewed journals and the legal press, and frequently speaks on intellectual property and litigation at business schools, universities and international conferences.


  • RIM -v- Visto.nMatthew was part of the team acting for Visto and working on the UK case involving RIM, which gained notoriety for the legal costs incurred by RIM. (link)
  • GUK (Mylan) -v- Yeda and Teva.nMatthew was the Senior Counsel at Teva with responsibility for this litigation in Europe, which saw success for Teva in multiple jurisdictions including at the UK Court of Appeal. (link)

Recent work

  • Acting for Unwired Planet International Limited in patent and FRAND litigation against Google, Samsung & Huawei (patents concerning Android, 2G, 3G and LTE technologies).

Published articles

  • June 2022
    Newsflash, Are open-source patent portfolios the key to the EV revolution? (link)
  • November 2021
    Lawyer Monthly , 5G need to understand to avoid infringing IP rights (link)
  • September 2021
    Med-Tech Innovation News, Time for medtech to wrap its head around 5G licensing (link)
  • September 2021
    Newsflash, License to heal (link)
  • August 2021
    Whitepaper, What's Next For Medtech? (link)
  • June 2019
    Managing Intellectual Property, There and back again: what it's like moving from in-house to private practice (link)
  • May 2019
    Financial Times, Should I patent my start-up product now or wait? (link)
  • November 2018
    Financial Times Alphaville, A modest proposal for the Open Data Institute (link)
  • July 2018
    Entrepreneur, Copyright, Elon Musk, and the Farting Unicorns of Doom (link)
  • July 2017
    Managing Intellectual Property Magazine, Copycat car makers and the role of design rights (link)
  • August 2015
    Real Business, The Google Patent Starter Program - What's it all about?
  • January 2015
    Real Business, Intellectual property rights and wrongs: Patents
  • October 2014
    SME web, IP Myth busting for SMEs
  • July 2014
    Landslide, The fall and rise of the Italian Torpoedo in European Patent Litigation (link)
  • June 2014
    JIPLP, Application for central amendment of a patent after revocation at first instance does not of itself render an appeal an abuse of process (link)
  • May 2014
    The IPKat, Another one bites the dust - Rovi v Virgin (link)
  • April 2014
    IP Law 360, SPCs - we wait in vain for clarity from Europe (link)
  • March 2014
    WTR Daily, Betty Boop character held to be badge of origin (link)

Education and qualifications

  • 2006 — 2007
    Postgraduate Diploma, University of Bristol
  • 1998 — 2001
    PhD in Biochemistry, University of Leicester
  • 1994 — 1997
    BSc (Hons) in Biochemistry, University of Bristol

Career history

  • 2014 — present
    Partner, EIP
  • 2011 — 2013
    Senior Counsel, Teva Pharmaceutical Industries Ltd
  • 2008 — 2011
    Associate, McDermott Will & Emery
  • 2005 — 2008
    Associate, Taylor Wessing

Awards and recognition

  • Recommended IAM Patent 1000, 2022. (link)
  • Legal 500, 2022. (link)
  • Recommended IAM Patent 1000, 2021. (link)
  • IAM Patent 1000, 2020. Matthew - "Does not limit his contentious prowess to his field of study". (link)
  • Legal 500, 2020 (link)
  • IAM Patent 1000, 2019. "His percipient understanding of life sciences litigation strategy is informed by deep industry knowledge". (link)
  • IAM Patent 1000, 2018. “Jones appreciates the unique day-to-day commercial pressures of the pharmaceutical industry”.
  • Legal 500, 2017: “Patent litigator Matt Jones has particular expertise in the technology sector, and is ‘sound on the technical details’”.
  • IAM Patent 1000, 2017. “Jones brings invaluable in-house experience to the squad”.
  • Recommended in Legal 500

Speaking engagements

  • March 2022
    EIP Webinar, Plausibility: The approach in the EPO & the UK
  • July 2020
    King's College School of Basic and Medical Biosciences Career event, From Biochemist graduate to a career in law
  • October 2019
    Roundtable, Intelligence Forums (link)
  • September 2019
    MIP European Patent Forum, Munich 2019, Conference Chair (link)
  • June 2016
    Future piracy - appropriation and production, (link)
  • November 2014
  • November 2014
    CASS Business School, IPRAW
  • October 2014
    Central Law Training, Intellectual Property: The “No-Patents” Round-Up For Non-Techie People Conference
  • October 2014
    The London IP Summit 2014, IP enforcement - challenges and trends
  • June 2016
    C5's 15th International Forum on Pharmaceutical Patent Term Extensions, SPCs for Medical Devices - Where are we now? (link)

Additional information

Member of European Patent Lawyers Association (EPLAW)